One‐year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization

Purpose To evaluate and compare the 12‐month outcomes of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization (CNV). Methods We retrospectively reviewed the medical records of 46 consecutive, treatment‐naive eyes which received intravitreal ranibizumab for subfoveal and juxtafoveal CNV secondary to pathologic myopia with a follow‐up of 12 months. Two groups were created according to different initial dosing regimens: group 1 included 25 eyes treated by a single intravitreal injection; group 2 included 21 eyes treated by three consecutive monthly injections. Additional injections were performed if needed. Patients' demographic data, best‐corrected visual acuity (BCVA), recurrence of CNV and total number of treatments were recorded and evaluated. Results There was no significant difference between two groups among baseline demographic data. At 12 months, the mean logMAR BCVA improved from 0.58 to 0.23 in group 1 and from 0.55 to 0.22 in group 2 (both p